Pharsight

1. Rubraca patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP16183844A	2020-04-30	Generics [UK] Ltd	Granted and Under Opposition
EP11708094A	2017-06-20	Hamm&Wittkopp Patentanwälte PartmbB	Granted and Under Opposition
EP11708094A	2017-06-20	Hexal AG / Sandoz International GmbH	Granted and Under Opposition
EP04798705A	2012-05-24	STRAWMAN LIMITED	Opposition procedure closed
EP04798705A	2012-05-24	Adams, Harvey Vaughan John	Opposition procedure closed
EP04743564A	2012-04-13	STRAWMAN LIMITED	Patent maintained as amended
EP04743564A	2012-04-13	Adams, Harvey Vaughan John	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8859562	October, 2011	Decision	Thomas Helleday

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6495541	CLOVIS ONCOLOGY INC	Tricyclic inhibitors of poly(ADP-ribose) polymerases	Nov, 2023 (a month from now)
US8754072	CLOVIS ONCOLOGY INC	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one	Feb, 2031 (7 years from now)
US9045487	CLOVIS ONCOLOGY INC	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one	Feb, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7531530	CLOVIS ONCOLOGY INC	Therapeutic compounds	Jul, 2024 (9 months from now)
US7351701	CLOVIS ONCOLOGY INC	Therapeutic compounds	Jul, 2024 (9 months from now)
US8071579	CLOVIS ONCOLOGY INC	DNA damage repair inhibitors for the treatment of cancer	Aug, 2027 (3 years from now)
US8143241	CLOVIS ONCOLOGY INC	DNA damage repair inhibitors for treatment of cancer	Aug, 2027 (3 years from now)
US9861638	CLOVIS ONCOLOGY INC	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one	Feb, 2031 (7 years from now)
US10278974	CLOVIS ONCOLOGY INC	Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one	Feb, 2031 (7 years from now)
US8859562	CLOVIS ONCOLOGY INC	Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer	Aug, 2031 (7 years from now)
US9987285	CLOVIS ONCOLOGY INC	High dosage strength tablets of rucaparib	Aug, 2035 (11 years from now)
US10130636	CLOVIS ONCOLOGY INC	High dosage strength tablets of rucaparib	Aug, 2035 (11 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 6, 2025
New Indication (I)	May 15, 2023

Drugs and Companies using RUCAPARIB CAMSYLATE ingredient

Market Authorisation Date: 19 December, 2016

Treatment: A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; A method for treating ovarian cancer by admin...

Dosage: TABLET;ORAL